Can I prescribe oseltamivir (Tamiflu) to an HIV‑positive patient taking Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), lamotrigine, meloxicam, risperidone, sumatriptan, tizanidine, zolpidem, and tamsulosin?

Can You Prescribe Tamiflu for an HIV-Positive Patient on Biktarvy and Multiple Concomitant Medications?

Yes, you can safely prescribe oseltamivir (Tamiflu) to this HIV-positive patient taking Biktarvy along with lamotrigine, meloxicam, risperidone, sumatriptan, tizanidine, zolpidem, and tamsulosin—there are no clinically significant drug-drug interactions between oseltamivir and any of these medications.

Drug Interaction Analysis

Biktarvy and Oseltamivir

• Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) has relatively few drug interactions compared to older antiretroviral regimens, particularly because it does not require pharmacokinetic boosting with ritonavir or cobicistat 1, 2.
• Oseltamivir is not metabolized through cytochrome P450 pathways and does not interact with the components of Biktarvy 3.
• The FDA label for Biktarvy emphasizes reviewing concomitant medications for potential interactions, but oseltamivir is not listed among contraindicated or interacting medications 3.

Other Concomitant Medications

• Lamotrigine: No interaction with oseltamivir; however, note that if this patient were on older boosted protease inhibitor regimens, lamotrigine levels could be affected, but Biktarvy does not have this issue 1.
• Meloxicam (NSAID): The primary concern with NSAIDs in HIV patients on tenofovir-containing regimens is potential nephrotoxicity, not drug-drug interactions with oseltamivir 3. Monitor renal function as clinically appropriate, especially since the Biktarvy label warns that patients taking nephrotoxic agents including NSAIDs are at increased risk of renal adverse reactions 3.
• Risperidone, sumatriptan, tizanidine, zolpidem, tamsulosin: None of these medications have documented interactions with oseltamivir or create contraindications for its use 3.

Important Clinical Considerations

Renal Function Monitoring

• Assess baseline renal function before prescribing oseltamivir, as dose adjustment may be needed in renal impairment 3.
• The combination of meloxicam (NSAID) with tenofovir alafenamide in Biktarvy warrants monitoring for renal toxicity, though TAF has a better renal safety profile than tenofovir disoproxil fumarate (TDF) 1, 3.
• The Biktarvy label specifically states: "Patients taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions" 3.

Biktarvy Stability and Viral Suppression

• Ensure the patient maintains adherence to Biktarvy during acute illness, as missing doses can lead to viral resistance development 3.
• Biktarvy has a high genetic barrier to resistance, making it more forgiving than older regimens, but consistent dosing remains critical 2, 4.

Prescribing Oseltamivir

Standard Dosing

• For influenza treatment: Oseltamivir 75 mg orally twice daily for 5 days (initiate within 48 hours of symptom onset for maximum benefit).
• For influenza prophylaxis: Oseltamivir 75 mg orally once daily for 10 days (post-exposure) or throughout the influenza season (pre-exposure).

Dose Adjustment

• If creatinine clearance is 30-60 mL/min: Reduce oseltamivir to 30 mg twice daily for treatment or 30 mg once daily for prophylaxis.
• If creatinine clearance is 10-30 mL/min: Reduce to 30 mg once daily for treatment or 30 mg every other day for prophylaxis.
• Note that Biktarvy is not recommended in patients with severe renal impairment (CrCl 15 to <30 mL/min) 3.

Common Pitfalls to Avoid

• Do not delay oseltamivir treatment while waiting to verify drug interactions—the evidence clearly supports safe co-administration with this medication regimen.
• Do not discontinue or adjust Biktarvy dosing when adding oseltamivir; no adjustment is needed 3.
• Monitor for NSAID-related renal toxicity in the context of tenofovir-containing regimens, but this is a baseline concern independent of oseltamivir use 3.
• Ensure the patient understands the importance of continuing Biktarvy even during acute illness, as treatment interruption can lead to viral rebound and resistance 3.